Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1996 Jul;72(849):403–408. doi: 10.1136/pgmj.72.849.403

Somatostatin analogue treatment of neuroendocrine tumours.

W W de Herder 1, A J van der Lely 1, S W Lamberts 1
PMCID: PMC2398518  PMID: 8935599

Abstract

The long-acting analogues of somatostatin have an established place in the medical treatment of patients with neuroendocrine tumours. They act through binding with specific, high-affinity membrane receptors. Somatostatin analogue therapy is an effective and safe treatment for most growth hormone and thyrothropin-secreting pituitary adenomas. The potential therapeutic consequences of the presence of somatostatin receptors on clinically 'nonfunctioning' pituitary tumours are still uncertain. Somatostatin analogues are not useful in the treatment of patients with prolactinomas, or adrenocorticotropin (ACTH)-secreting adenomas. However, the somatostatin analogue octreotide suppressed pathological ACTH release in some patients with Nelson's syndrome and ACTH and cortisol secretion in several patients with Cushing's syndrome caused by ectopic ACTH secretion. Somatostatin analogues are effective in the sympatomatic treatment of most (metastatic) pancreatic islet cell tumours and most (metastatic) carcinoids. In some of these patients, they also induce tumour stabilisation or reduction. In some patients with (metastatic) medullary thyroid carcinomas, continuous treatment with very high doses of octreotide can be of temporary relief. The clinical effectiveness of somatostatin analogues in patients with small cell lung cancer is currently under investigation. Long-term therapy with somatostatin analogues of catecholamine-secreting (malignant) paragangliomas and phaeochromocytomas has not shown clinical benefits.

Full text

PDF
406

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol. 1995 Mar;132(3):320–325. doi: 10.1530/eje.0.1320320. [DOI] [PubMed] [Google Scholar]
  2. Chanson P., Weintraub B. D., Harris A. G. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med. 1993 Aug 1;119(3):236–240. doi: 10.7326/0003-4819-119-3-199308010-00010. [DOI] [PubMed] [Google Scholar]
  3. Ezzat S., Snyder P. J., Young W. F., Boyajy L. D., Newman C., Klibanski A., Molitch M. E., Boyd A. E., Sheeler L., Cook D. M. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992 Nov 1;117(9):711–718. doi: 10.7326/0003-4819-117-9-711. [DOI] [PubMed] [Google Scholar]
  4. Frank-Raue K., Ziegler R., Raue F. The use of octreotide in the treatment of medullary thyroid carcinoma. Horm Metab Res Suppl. 1993;27:44–47. [PubMed] [Google Scholar]
  5. Jørgensen J. O., Møller N., Møller J., Weeke J., Blum W. F. Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism. 1994 May;43(5):579–583. doi: 10.1016/0026-0495(94)90199-6. [DOI] [PubMed] [Google Scholar]
  6. Krenning E. P., Kwekkeboom D. J., Bakker W. H., Breeman W. A., Kooij P. P., Oei H. Y., van Hagen M., Postema P. T., de Jong M., Reubi J. C. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716–731. doi: 10.1007/BF00181765. [DOI] [PubMed] [Google Scholar]
  7. Kvols L. K., Reubi J. C. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol. 1993;32(2):197–201. doi: 10.3109/02841869309083912. [DOI] [PubMed] [Google Scholar]
  8. Kvols L. K. Therapeutic considerations for the malignant carcinoid syndrome. Acta Oncol. 1989;28(3):433–438. doi: 10.3109/02841868909111218. [DOI] [PubMed] [Google Scholar]
  9. Lamberts S. W., Hofland L. J., de Herder W. W., Kwekkeboom D. J., Reubi J. C., Krenning E. P. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol. 1993 Jan;14(1):27–55. doi: 10.1006/frne.1993.1002. [DOI] [PubMed] [Google Scholar]
  10. Lamberts S. W., Krenning E. P., Reubi J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991 Nov;12(4):450–482. doi: 10.1210/edrv-12-4-450. [DOI] [PubMed] [Google Scholar]
  11. Lamberts S. W. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988 Nov;9(4):417–436. doi: 10.1210/edrv-9-4-417. [DOI] [PubMed] [Google Scholar]
  12. Lamberts S. W., de Herder W. W., Krenning E. P., Reubi J. C. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab. 1994 Jan;78(1):17–19. doi: 10.1210/jcem.78.1.7904612. [DOI] [PubMed] [Google Scholar]
  13. Lamberts S. W., de Herder W. W., Kwekkeboom D. J., vd Lely A. J., Nobels F. R., Krenning E. P. Current tools in the diagnosis of pituitary tumours. Acta Endocrinol (Copenh) 1993 Jul;129 (Suppl 1):6–12. [PubMed] [Google Scholar]
  14. Mahler C., Verhelst J., de Longueville M., Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 1990 Aug;33(2):261–269. doi: 10.1111/j.1365-2265.1990.tb00490.x. [DOI] [PubMed] [Google Scholar]
  15. Merola B., Colao A., Ferone D., Selleri A., Di Sarno A., Marzullo P., Biondi B., Spaziante R., Rossi E., Lombardi G. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res. 1993;40(4):149–155. doi: 10.1159/000183785. [DOI] [PubMed] [Google Scholar]
  16. Modigliani E., Chayvialle J. A., Cohen R., Perret G., Guliana J. M., Vassy R., Roger P., Siame-Mourot C., Bennet M., Bentata-Pessayre M. Effect of a somatostatin analog (SMS 201-995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma. Horm Metab Res. 1988 Dec;20(12):773–775. doi: 10.1055/s-2007-1010946. [DOI] [PubMed] [Google Scholar]
  17. Modigliani E., Cohen R., Joannidis S., Siame-Mourot C., Guliana J. M., Charpentier G., Cassuto D., Bentata Pessayre M., Tabarin A., Roger P. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1992 Feb;36(2):183–186. doi: 10.1111/j.1365-2265.1992.tb00955.x. [DOI] [PubMed] [Google Scholar]
  18. Moertel C. G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987 Oct;5(10):1502–1522. doi: 10.1200/JCO.1987.5.10.1502. [DOI] [PubMed] [Google Scholar]
  19. Morange I., De Boisvilliers F., Chanson P., Lucas B., DeWailly D., Catus F., Thomas F., Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 1994 Jul;79(1):145–151. doi: 10.1210/jcem.79.1.8027218. [DOI] [PubMed] [Google Scholar]
  20. Pearse A. G., Takor T. T. Neuroendocrine embryology and the APUD concept. Clin Endocrinol (Oxf) 1976;5 (Suppl):229S–244S. doi: 10.1111/j.1365-2265.1976.tb03832.x. [DOI] [PubMed] [Google Scholar]
  21. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993 Oct 21;329(17):1246–1253. doi: 10.1056/NEJM199310213291708. [DOI] [PubMed] [Google Scholar]
  22. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  23. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  24. Reubi J. C., Laissue J., Krenning E., Lamberts S. W. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):27–35. doi: 10.1016/0960-0760(92)90184-k. [DOI] [PubMed] [Google Scholar]
  25. Wynick D., Anderson J. V., Williams S. J., Bloom S. R. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf) 1989 Apr;30(4):385–388. doi: 10.1111/j.1365-2265.1989.tb00436.x. [DOI] [PubMed] [Google Scholar]
  26. Wynick D., Bloom S. R. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab. 1991 Jul;73(1):1–3. doi: 10.1210/jcem-73-1-1. [DOI] [PubMed] [Google Scholar]
  27. de Bruin T. W., Kwekkeboom D. J., Van't Verlaat J. W., Reubi J. C., Krenning E. P., Lamberts S. W., Croughs R. J. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 1992 Nov;75(5):1310–1317. doi: 10.1210/jcem.75.5.1430093. [DOI] [PubMed] [Google Scholar]
  28. de Herder W. W., Krenning E. P., Malchoff C. D., Hofland L. J., Reubi J. C., Kwekkeboom D. J., Oei H. Y., Pols H. A., Bruining H. A., Nobels F. R. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med. 1994 Apr;96(4):305–312. doi: 10.1016/0002-9343(94)90059-0. [DOI] [PubMed] [Google Scholar]
  29. de Herder W. W., Uitterlinden P., van der Lely A. J., Hofland L. J., Lamberts S. W. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. Eur J Endocrinol. 1995 Aug;133(2):195–199. doi: 10.1530/eje.0.1330195. [DOI] [PubMed] [Google Scholar]
  30. van der Lely A. J., Harris A. G., Lamberts S. W. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 1992 Aug;37(2):181–185. doi: 10.1111/j.1365-2265.1992.tb02304.x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES